Cencora, Inc. (NYSE:COR) Shares Acquired by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC lifted its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 3.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 94,236 shares of the company's stock after acquiring an additional 3,118 shares during the period. Chevy Chase Trust Holdings LLC's holdings in Cencora were worth $21,211,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Lake Street Advisors Group LLC lifted its stake in Cencora by 1.3% in the third quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company's stock valued at $769,000 after acquiring an additional 43 shares during the last quarter. Financial Advocates Investment Management lifted its stake in shares of Cencora by 4.7% during the 2nd quarter. Financial Advocates Investment Management now owns 978 shares of the company's stock worth $220,000 after buying an additional 44 shares during the last quarter. Venturi Wealth Management LLC lifted its stake in shares of Cencora by 1.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company's stock worth $1,001,000 after buying an additional 46 shares during the last quarter. Prime Capital Investment Advisors LLC lifted its stake in shares of Cencora by 1.2% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company's stock worth $848,000 after buying an additional 46 shares during the last quarter. Finally, Checchi Capital Advisers LLC lifted its stake in shares of Cencora by 2.2% during the 2nd quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company's stock worth $499,000 after buying an additional 48 shares during the last quarter. Institutional investors own 97.52% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on COR. Barclays raised their price target on shares of Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. UBS Group raised their price target on shares of Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. raised their target price on shares of Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a report on Wednesday, August 21st. Robert W. Baird raised their target price on shares of Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. Finally, Evercore ISI raised their target price on shares of Cencora from $250.00 to $285.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $276.80.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 21,509 shares of the business's stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the sale, the chairman now owns 306,752 shares in the company, valued at approximately $74,283,064.32. The trade was a 6.55 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 93,018 shares of company stock valued at $22,478,942 in the last three months. Corporate insiders own 15.80% of the company's stock.

Cencora Stock Down 0.6 %

Shares of NYSE:COR traded down $1.58 during trading on Wednesday, reaching $248.47. 1,002,357 shares of the stock traded hands, compared to its average volume of 1,390,989. The stock has a 50-day moving average of $236.34 and a two-hundred day moving average of $233.11. Cencora, Inc. has a 52-week low of $195.83 and a 52-week high of $253.27. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The stock has a market cap of $48.96 billion, a P/E ratio of 33.09, a price-to-earnings-growth ratio of 1.66 and a beta of 0.45.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were issued a $0.55 dividend. This is an increase from Cencora's previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date was Friday, November 15th. Cencora's payout ratio is currently 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.